Drugmakers engage in ‘co-opetition’ through drug middlemen
Consumers can pretty easily discern how automobile manufacturers and their suppliers make money, for example. But fewer understand how their $20 co-pay for anti-cholesterol medication gets split between the drugmaker, the insurance company and the pharmacy benefit manager. New research from Olin Business School aims to explain.